Targeting CD39 in Cancer

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2020 Jul 31

PMID 32728220

Citations 152

Authors

Achim K Moesta

Xian-Yang Li

Mark J Smyth

Affiliations

Soon will be listed here.

Abstract

The ATP-adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumour microenvironment. Consequently, multiple clinical strategies are being explored to target this pathway for the treatment of cancer; in particular, recent clinical data with CD73 antagonists and inhibitors of A receptors have demonstrated the therapeutic potential of modulating this pathway. Now, inhibitors of the ectonucleotidase CD39, the rate-limiting enzyme in the conversion of ATP to immunomodulatory adenosine, are entering clinical trials. Consequently, there is currently a focus on understanding the impact of CD39 enzymatic function on innate and adaptive immunity and how therapeutic modulation of this pathway alters their functional potential within the tumour microenvironment. Recent findings reveal multipronged mechanisms of action of CD39 antagonism that rely not only on preventing the accumulation of adenosine but also on the stabilization of pro-inflammatory extracellular ATP to restore antitumour immunity. Here, we review the impact of CD39 expression and ectonucleotidase activity on immunity with a focus on the setting of oncology. Additionally, we discuss the implications for immunotherapy strategies targeting CD39, including their inclusion in rational combination therapies.

Citing Articles

Immunogenic cell death signature predicts survival and reveals the role of VEGFA + Mast cells in lung adenocarcinoma.

Zhang M, Zhou G, Xu Y, Wei B, Liu Q, Zhang G Sci Rep. 2025; 15(1):7213.

PMID: 40021802 PMC: 11871002. DOI: 10.1038/s41598-025-91401-5.

Predictive circulating biomarkers of the response to anti-PD-1 immunotherapy in advanced HER2 negative breast cancer.

Wei Y, Ge H, Qi Y, Zeng C, Sun X, Mo H Clin Transl Med. 2025; 15(3):e70255.

PMID: 40000397 PMC: 11859116. DOI: 10.1002/ctm2.70255.

Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies.

Wang H, Zhou F, Qin W, Yang Y, Li X, Liu R Theranostics. 2025; 15(6):2159-2184.

PMID: 39990210 PMC: 11840731. DOI: 10.7150/thno.105276.

Bacteria invade the brain following intracortical microelectrode implantation, inducing gut-brain axis disruption and contributing to reduced microelectrode performance.

Hoeferlin G, Grabinski S, Druschel L, Duncan J, Burkhart G, Weagraff G Nat Commun. 2025; 16(1):1829.

PMID: 39979293 PMC: 11842729. DOI: 10.1038/s41467-025-56979-4.

Bioinformatics-based identification of CTSS, DOK2, and ENTPD1 as potential blood biomarkers of schizophrenia.

Zhang L, Zhang J, Wang N, Liu C, Wang S, Dong X BMC Psychiatry. 2025; 25(1):157.

PMID: 39972407 PMC: 11841330. DOI: 10.1186/s12888-025-06512-0.

References

Ohta A, Sitkovsky M . Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 2002; 414(6866):916-20. DOI: 10.1038/414916a. View

Huang S, Apasov S, Koshiba M, Sitkovsky M . Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 1997; 90(4):1600-10. View

Wolberg G, Zimmerman T, Hiemstra K, Winston M, Chu L . Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate. Science. 1975; 187(4180):957-9. DOI: 10.1126/science.167434. View

Ohta A, Gorelik E, Prasad S, Ronchese F, Lukashev D, Wong M . A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006; 103(35):13132-7. PMC: 1559765. DOI: 10.1073/pnas.0605251103. View

Kaczmarek E, Koziak K, Sevigny J, Siegel J, Anrather J, BEAUDOIN A . Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem. 1996; 271(51):33116-22. DOI: 10.1074/jbc.271.51.33116. View

Enjyoji K, Sevigny J, Lin Y, Frenette P, Christie P, Esch 2nd J . Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 1999; 5(9):1010-7. DOI: 10.1038/12447. View

Deaglio S, Dwyer K, Gao W, Friedman D, Usheva A, Erat A . Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204(6):1257-65. PMC: 2118603. DOI: 10.1084/jem.20062512. View

Jackson S, Hoshi T, Wu Y, Sun X, Enjyoji K, Cszimadia E . Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am J Pathol. 2007; 171(4):1395-404. PMC: 1988887. DOI: 10.2353/ajpath.2007.070190. View

Allard B, Longhi M, Robson S, Stagg J . The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev. 2017; 276(1):121-144. PMC: 5338647. DOI: 10.1111/imr.12528. View

10.

Hatfield S, Veszeleiova K, Steingold J, Sethuraman J, Sitkovsky M . Mechanistic Justifications of Systemic Therapeutic Oxygenation of Tumors to Weaken the Hypoxia Inducible Factor 1α-Mediated Immunosuppression. Adv Exp Med Biol. 2019; 1136:113-121. DOI: 10.1007/978-3-030-12734-3_8. View

11.

Vijayan D, Young A, Teng M, Smyth M . Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017; 17(12):709-724. DOI: 10.1038/nrc.2017.86. View

12.

Young A, Mittal D, Stagg J, Smyth M . Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014; 4(8):879-88. DOI: 10.1158/2159-8290.CD-14-0341. View

13.

Boison D, Yegutkin G . Adenosine Metabolism: Emerging Concepts for Cancer Therapy. Cancer Cell. 2019; 36(6):582-596. PMC: 7224341. DOI: 10.1016/j.ccell.2019.10.007. View

14.

Mascanfroni I, Takenaka M, Yeste A, Patel B, Wu Y, Kenison J . Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat Med. 2015; 21(6):638-46. PMC: 4476246. DOI: 10.1038/nm.3868. View

15.

Takenaka M, Gabriely G, Rothhammer V, Mascanfroni I, Wheeler M, Chao C . Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019; 22(5):729-740. PMC: 8052632. DOI: 10.1038/s41593-019-0370-y. View

16.

Bastid J, Regairaz A, Bonnefoy N, Dejou C, Giustiniani J, Laheurte C . Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res. 2014; 3(3):254-65. DOI: 10.1158/2326-6066.CIR-14-0018. View

17.

Hayes G, Cairns B, Levashova Z, Chinn L, Perez M, Theunissen J . CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. Am J Transl Res. 2015; 7(6):1181-8. PMC: 4532750. View

18.

Pulte D, Furman R, Broekman M, Drosopoulos J, Ballard H, Olson K . CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011; 11(4):367-72. PMC: 3590911. DOI: 10.1016/j.clml.2011.06.005. View

19.

Hausler S, Montalban Del Barrio I, Strohschein J, Chandran P, Engel J, Honig A . Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother. 2011; 60(10):1405-18. PMC: 11028787. DOI: 10.1007/s00262-011-1040-4. View

20.

Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D . Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. 2010; 107(4):1547-52. PMC: 2824381. DOI: 10.1073/pnas.0908801107. View